



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Final Program

2nd WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE 2009

“Psoriasis – Skin and Beyond”
June 24 – 28 2009, Stockholm, Sweden



Photo by Olof Holdar

www.ifpa-pso.org

Content

2nd World Psoriasis & Psoriatic Arthritis Conference 2009

Welcome	p. 4
- IFPA President	
- Scientific Executive Committee	
Committees	p. 5
Scientific Program	p. 6
Registration	p. 12
Important Adresses	p. 12
Social Program	p. 13
General Information	p. 16
Stockholm and Sweden	p. 17
Abstracts	p. 19

Patron of the 2nd World Psoriasis & Psoriatic Arthritis Conference



His Majesty King Carl Gustav

Welcome

Dear Friend,

On behalf of the International Federation of Psoriasis Associations, IFPA, it is my great honor to invite you to the 2nd World Psoriasis and Psoriatic Arthritis Conference 2009, which will take place in Stockholm, Sweden, June 24-28, 2009.

In 2006 IFPA organized, together with leading dermatologists and rheumatologists, the 1st Psoriasis and Psoriatic Arthritis Conference in Stockholm. The purpose was to assemble dermatologists and rheumatologists and, for the first time ever, have a joint high-level scientific discussion and approach to our disease. The conference became a great success and IFPA was therefore asked to organize a second conference in 2009.

The theme for 2009 is "Psoriasis - Skin and Beyond" which recognizes the many diverse and emerging issues involved with psoriasis and associated conditions.

We now know that there are several other medical problems than psoriasis arthritis linked to psoriasis, e.g. risk for cardiovascular conditions, eye problems, inflammatory bowel diseases, diabetes and obesity. The purpose of the conference is to bring all aspects of the psoriasis patient together in one conference and from a patient's point of view discuss new scientific facts and studies.

The scientific program is strongly influenced by an IFPA Worldwide survey conducted in 2008, where important topics have been

identified from the patient's perspective. On the basis of the survey findings, the Scientific Executive Committee has been able to create a conference program which covers almost all aspects of the psoriasis disease from a scientific point of view. We have also included a complementary program for allied health professionals; nurses, physiotherapists and others.

I am therefore confident that the 2nd World Conference will be a common platform for all specialists involved in research and treatment of our disease, in their efforts to give the psoriasis patients around the world better and more effective treatment methods and a better quality of life. I also hope the conference will be a major contribution to our joint efforts to have psoriasis recognized as a serious systemic chronic inflammatory noncommunicable disease by all responsible national authorities and the World Health Organization, WHO.

Yours sincerely,



Lars Ettarp
President of IFPA

Dear Colleague,

In 2006, the International Federation of Psoriasis Associations, IFPA, organized the 1st World Psoriasis and Psoriatic Arthritis Conference in Stockholm. About 700 delegates from 47 countries attended the conference which provided a unique environment for open exchange between health care professionals from various backgrounds who care for psoriasis patients. The success of the meeting documented the need for an ongoing interaction and communication that will allow researchers, clinicians and patients to keep pace with the tremendous progress that is unfolding in all areas related to psoriasis.


It is now our great pleasure and honour to invite you to the 2nd World Psoriasis and Psoriatic Arthritis Conference that will take place in Stockholm in June 2009. We have developed an ambitious conference program that addresses a broad spectrum of scientific, clinical and practical, aspects of psoriasis and related disorders. The lectures will be delivered by leading world experts who will share their knowl-

edge and experience with opportunities for interactive discussions. In addition, a call for abstracts on relevant psoriasis issues will provide a forum for presentation of the most recent progress in clinical and experimental research in order to facilitate additional discussion and collaboration.

As such, we expect that the conference program will combine cutting edge presentations with a learning environment that will maximize interaction between physicians and scientists. It is also anticipated that these interactions, will enhance communication between patients and health professionals and catalyze new research efforts in psoriatic disease.

We look forward to welcoming you at the 2nd World Psoriasis and Psoriatic Arthritis Conference in Stockholm and we are confident that you will find the program stimulating and enjoyable.

Sincerely,



Prof. Joerg C. Prinz
President of the 2nd World
Psoriasis and Psoriatic Arthritis
Conference 2009
Chairman of the Scientific
Executive Committee



Prof. Mona Stähle
Co-chair of the Scientific
Executive Committee



Prof. Christopher Ritchlin
Co-chair of the Scientific
Executive Committee

Committees

Scientific Executive Committee

Chairman

Prof. Joerg C. Prinz
University of Munich, Munich, GERMANY

Co-Chair

Prof. Mona Ståhle
Karolinska Institutet, Stockholm, SWEDEN

Co-Chair

Prof. Christopher Ritchlin
University of Rochester Medical Center, New York, USA

Council of Scientific Advisors

Dr. Dominique Baeten
University of Amsterdam, Netherlands

Dr. Juan Canete
Hospital Clínic, Spain

Prof. Enno Christophers
University of Schleswig Holstein Kiel, Germany

Prof. Sergio Chimenti
University of Rome Tor Vergata, Italy

Prof. Louis Dubertret,
Psoriasis International Network, France

Prof. Luis Espinosa
LSU Health Sciences Center, USA

Ass. Prof. David Fiorentino
Stanford school of medicine, Spain

Ass. Prof. Amit Garg
University of Massachusetts, USA

Dr. Wayne Gulliver,
NewLab Clinical research, Canada

Dr. Elaine Husni
Cleveland Clinic, USA

Prof. Knud Kragballe
Århus University Hospital, Denmark

Prof. Richard Langley,
Dalhousie University, USA

Prof. Robert Landew
University Hospital Maastricht, Netherlands

Dr. Ennio Lubrano
Scientific Institute of Telesse Terme, Italy

Prof. Dennis McGonagle
University of Leeds, UK

Prof. Ulrich Mrowietz
University of Kiel, Germany

Prof. Mikkel Ostergaard,
Copenhagen University Hospitals at Herlev and Hvidovre, Denmark

Dr. Ignazio Olivieri,
San Carlo Hospital, Italy

Prof. Constantino Pitzalis
Barts and the London School of Medicine and Dentistry, UK

Ass. Prof. Louis Puig,
Universitat Autònoma de Barcelona, Spain

Dr. Proton Rahman
Memorial University of Newfoundland Canada

Dr. Murlidhar Rajagopalan
Apollo hospitals, India

Dr. Anthony Russell
University of Alberta, Canada

Prof. Thomas Ruzicka,
University of Munich, Germany

Prof. Raffaele Scarpa
University of Napoli, Italy

Dr. Enrique Soriano
Hospital Italiano de Buenos Aires, Argentina

Paul Peter Tak
University of Amsterdam Netherlands

Dr. Tsen-Fang Tsai
National Taiwan University Hospital, Taiwan

Prof. Gail Todd
University of Cape Town, South Africa

Dr. Kurt de Vlam
University Hospitals Leuven, Belgium

Scientific Program Committee

Dermatology

Prof. Kenneth Gordon,
Loyola University Medical Center, Illinois, USA

Prof. Christopher Griffith,
University of Manchester, Manchester, UK

Prof. Peter van de Kerkhof,
University Medical Centre Nijmegen, Nijmegen, The Netherlands

Dr. Alan Menter,
Baylor Research Institute, Dallas, USA

Rheumatology

Prof. Dafna Gladman,
Toronto Western Hospital, Toronto, CANADA

Dr. Philip Helliwell,
University of Leeds, Leeds, UK

Prof. Arthur Kavanaugh,
The University of California, San Diego, USA

Dr. Philip Mease.
Seattle Rheumatology Associates, USA

IFPA Medical Advisors

Prof. Mark Lebwohl, USA

Prof. Peter van de Kerkhof, The Netherlands

Organizing Committee

Chairman

Prof. Joachim Barth,
Treasurer of IFPA, GERMANY

Lars Ettarp,
President of IFPA, SWEDEN

Dr. Hoseah Waweru,
Vice President of IFPA, KENYA

Kathleen Gallant,
Secretary of IFPA, USA

Valgerdur Audunsdottir,
Member at large of IFPA, ICELAND

IFPA Secretariat



Scientific Program

Time	GENERAL PROGRAM	Time	COMPLEMENTARY PROGRAM
------	-----------------	------	-----------------------

WEDNESDAY JUNE 24TH

08.00-17.00	Pre-Conference meetings
15.00-18.00	REGISTRATION
18.00-19.30	Welcome reception

THURSDAY JUNE 25TH

07.30	Registration		
08.30 – 09.00	Opening ceremony Speakers: Lars Ettarp President of IFPA, Prof. Göran Hansson, Secretary of the Nobel Committee for physiology or medicine and member of the Board of Directors of the Nobel Foundation, Prof. Joerg C. Prinz, Prof. Christopher Ritchlin		
09.00 – 10.00	PLENARY 1. PSORIASIS: MORE THAN SKIN DEEP Chairs: Prof. Dennis McGonagle and Dr. David Fiorentino		
20 minutes	Psoriasis: what is it? Classification and phenotype Speaker: Dr. Alan Menter		
20 minutes	Skin and bone: The pathogenetic relationship between psoriasis and psoriatic arthritis Speaker: Prof. Christopher Ritchlin		
20 minutes	The collateral damage: Co-morbidities and life expectancy Speaker: Dr Joel Gelfand		
10.00 – 10.30	Poster Session and Exhibits		
10.30 – 12.00	PLENARY 2. LIVING WITH PSORIASIS Chairs: Dr. Hoseah Waweru and Dr. Elaine Husni		
20 minutes	The outcasts: Living with stigmatization Speaker: Prof. G Schmid-Ott		
20 minutes	Making it worse: Triggers and risk factors for psoriasis and psoriatic arthritis Speaker: Dr. Luigi Naldi		
20 minutes	Stressing psoriasis: the psychosocial impact Speaker: Dr. Francesca Sampogna		
20 minutes	Patient education: What do psoriasis patients need to learn? Speaker: Dr. Anna-Lene Krogstad		
10 minutes	Abstract presentation Abstract No: 91 - Quality of life in psoriatic patients from Buenos Aires Argentina		
12.00 – 13.30	Posters/Exhibits		
12.15 – 13.15	Lunch seminar - Schering-Plough, The Auditorium, Norra Latin New Views on Nail Anatomy and Psoriasis		
13.30 – 15.30	PLENARY 3. PSORIASIS: GOING ASTRAY Chairs: Dr. Kurt de Vlam and Prof. Jean Saurat	13.30 – 15.30	COMPLEMENTARY PROGRAM, room 307 Chair: Dr. Hoseah Waweru
20 minutes	Early diagnosis of psoriatic arthritis: Is enthesitis the primary lesion? Speaker: Dr. Philip Helliwell	20 minutes	Introduction to the complementary program Speaker: Prof. Joachim Barth
20 minutes	Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum	40 minutes	From a physiotherapeutic point of view Speaker: Prof. Christina H. Opava

Time	GENERAL PROGRAM	Time	COMPLEMENTARY PROGRAM
20 minutes	Standing straight: spinal disease in psoriasis Speaker: Prof. Dafna Gladman		
20 minutes	Psoriasis treatment and the risk of infection, cancer and lymphoma: what do registries tell us? Speaker: Prof. Gerald G Krueger	20 minutes	Swedish treatment centers – a holistic approach Speaker: Lars Ettarp, President of the Swedish Psoriasis Association
20 minutes	Psoriasis and cardiovascular complications Speaker: Prof. Wolf-Henning Boehncke	20 minutes	Psychosocial issues and developing effective support in Psoriasis Speaker: Prof. Steve Ersser
20 minutes	Abstract presentations Abstract No: 41 - Metabolic syndrome at psoriasis onset and at long-term follow-up of psoriasis: A prospective cohort study Abstract No: 42 - Inflammation: A pivotal link between psoriatic arthritis and atherosclerosis including case reports		
15.30 – 16.00	Coffee/Posters/Exhibits		
16.00 – 16.30	Key note lecture THE INFLAMMATORY BASIS OF ATHEROSCLEROSIS: Aggravation by chronic immune mediated inflammatory disorders? Speaker: Prof. Göran Hansson		
16.45 – 17.45	Satellite Symposium - Wyeth, room 202 More than skin deep: Changing management practises in psoriatic disease		

FRIDAY JUNE 26TH

07.30 – 08.30	Posters/Exhibits		
08.30 – 09.00	Key note lecture PSORIASIS THROUGH GENERATIONS: the genetic predisposition of psoriasis and psoriatic arthritis Speaker: Prof. James T. Elder		
09.00 – 10.00	PLENARY 4. THE PSORIASIS FAMILY Chairs: Dr. Wayne Gulliver and Dr. Hyon Choi		
20 minutes	Family members and partners: 1st degree sufferers Speaker: Prof. Andrew Y Finlay		
20 minutes	Family planning and psoriasis treatment: contraception, pregnancy and lactation Speaker: Ass. Prof. Alexa Kimball		
20 minutes	Psoriasis and psoriatic arthritis in childhood: therapeutic challenges Speaker: Prof. Amy Paller		
10.00 – 10.30	Poster Session and Exhibits		
10.30 – 12.00	PLENARY 5. PSORIASIS: FROM BENCH TO PATIENT Chairs: Dr. Proton Rahman and Chair Prof. Herve Bachelez	10.30 – 12.00	COMPLEMENTARY PROGRAM room 307 Chair: Prof. Joachim Barth
20 minutes	Step by step: Dissecting pathogenic events in psoriasis Speaker: Prof. Frank Nestle	20 minutes	Topical therapy - Easy, available and not to be forgotten Speaker: Dr. Desiree Wiegleb-Edström
20 minutes	Cytokines and synovial biology Speaker: Prof. Ian B McInnes	20 minutes	Photo therapy and photo chemotherapy - When topical treatment are insufficient Speaker: Prof. Joachim Barth
20 minutes	MicroRNAs: regulators of skin inflammation Speaker: Prof. Mona Stähle	20 minutes	Photosensitivity and photo allergy Speaker: Dr. Anders Ljungberg
20 minutes	Psoriatic autoantigens: a chance for vaccination? Speaker: Prof. Joerg C. Prinz	20 minutes	Systemic therapy - i.e. Biologics, Methotrexate, Cyclosporine, Retinoids Speaker: Dr. Jonas F Eriksson

Time	GENERAL PROGRAM	Time	COMPLEMENTARY PROGRAM
10 minutes	Abstract presentation Abstract No: 4 - The molecular profile of psoriatic skin in responders to ustekinumab or etanercept following twelve weeks of treatment: Results from the ACCEPT Trial		
12.00 – 13.30	Posters/Exhibits		
12.15 – 13.15	Lunch seminar - Janssen Cilag, The Auditorium, Norra Latin IL-12/IL-23: New therapeutic targets in the treatment of immune-mediated inflammatory diseases		
13.30 – 15.30	PLENARY 6. TREATMENT AND PERSPECTIVES Chairs: Prof. Enno Christophers and Dr. Anthony Russel		
20 minutes	Treatment of psoriasis: stepwise escalation from conventional systemics to biologics? Speaker: Prof. Kenneth B. Gordon		
20 minutes	Hit hard and early: Can progression of psoriasis be prevented? Speaker: Prof. Neil McHugh		
20 minutes	Should I take this medicine? Risks versus benefits of psoriasis therapy Speaker: Prof. Jonathan Barker		
20 minutes	Can efficient treatment of psoriasis prevent inflammation-related comorbidities? Lessons from rheumatoid arthritis Speaker: Prof. Oliver Fitzgerald		
20 minutes	Biologics: today and tomorrow Speaker: Prof. Alice B. Gottlieb		
20 minutes	Abstract presentations Abstract No: 52 - Achieving minimal disease activity (MDA) criteria decreases progression of joint damage in PSA Abstract No: 114 - Statins in the treatment of psoriasis - friend or foe?		
15.30 – 16.00	Poster Session and Exhibits		
16.00 – 16.30	Key note lecture OBESITY, METABOLIC SYNDROME AND PSORIASIS: the slimmer - the better? Speaker: Prof. Peter Arner		
16.45 – 17.45	Satellite Symposium - Abbott, The Auditorium, Norra Latin Dermatology & Rheumatology: Sharing the experience of using anti-TNFs in psoriatic diseases		

SATURDAY JUNE 27TH

07.30 – 08.30	Posters/Exhibits		
08.30 – 09.30	PLENARY 7. PSORIASIS CARE Chairs: Prof. Luis Puig and Prof. Mikkel Ostergaard		
20 minutes	Psoriasis and stress: the holistic model for management of psoriasis. Role of the care team? Speaker: Prof. FA Tausk		
20 minutes	Identifying risk Profiles: developing patient questionnaires Speaker: Dr Abrar A. Qureshi		
20 minutes	The importance of patient satisfaction in psoriasis treatment Speaker: Prof. Stephen Feldman		
09.30 – 10.00	Key note lecture THE REVOLUTION IN PSORIASIS TREATMENT: Selective interference with pathogenesis. Speaker: Prof. James G. Krueger		
10.00 – 10.30	Posters/Exhibits		
10.30 – 12.00	PLENARY 8. HEALTH ECONOMICS AND HEALTH POLITICS Chairs: Dr. Luis R. Espinoza and Prof. Gail Todd		
20 minutes	The rich and the poor: Global limitations in the access to treatment. Speaker: Dr. John Masenga		
20 minutes	Threats and opportunities for Patient groups Speaker: Dr. Mary Baker		

Time	GENERAL PROGRAM	Time	COMPLEMENTARY PROGRAM
20 minutes	The economic burden of psoriasis and psoriatic arthritis Speaker: Prof. Arthur Kavanaugh		
20 minutes	Community participation: Who benefits? Speaker: Dr. Will Taylor		
10 minutes	Abstract presentation Abstract No: 115 - Quality of care and research profiles: Results of an International Psoriasis Council (IPC) exercise		
12.00 – 13.30	Posters/Exhibits		
12.15 – 13.15	Lunch seminar - International Psoriasis Council, IPC, hall c Meet the experts, a case-based learning discussion		
13.30 – 15.00	PLENARY 9. ASSESSING SEVERITY, FOLLOWING PROGRESSION Chairs: Professor Sergio Chimenti and Dr. Ignazio Olivieri	13.30 – 15.30	COMPLEMENTARY PROGRAM room 307 Chair: Prof. Joachim Barth
20 minutes	Psoriasis - defining severity. National Psoriasis Foundation clinical consensus on disease severity Speaker: Prof. Mark Lebwohl,	20 minutes	Pustulosis palmoplantaris - Painful and hard to treat Speaker: Dr. Birgitta Wilson Claréus
20 minutes	Psoriasis and psoriatic arthritis: Can remission be achieved? Speaker: Prof. Philip Mease	20 minutes	Psoriasis does not stop at the ankles - The importance of podiatric care Speaker: Gunnel Köhler
20 minutes	Imaging: assessing severity and activity of psoriatic arthritis by ultrasonography, MRT and CT Speaker: Ass. Prof. Fiona McQueen	20 minutes	Drugs/Medications that deteriorates psoriasis Speaker: Ms Karina Jackson
20 minutes	Practical issues during sytemic treatment Speaker: Prof. Paul Emery	20 minutes	PASI-score – educational session Speaker: Dr. Anne-Lene Krogstad
10 minutes	Abstract presentation Abstract No: 99 - Development of a composite disease activity score in psoriatic arthritis		
15.00 – 15.30	Poster Session and Exhibits		
15.30 – 16.30	CONCLUDING LECTURES Chairs: Prof. Paul P. Tak and Prof. Richard Langley		
20 minutes	Psoriatic arthritis: coping or curing? Speaker: Dr. Douglas Veale		
20 minutes	Psoriasis care: Quo vadis? Prof. Christopher Griffiths		
20 minutes	Psoriasis patients: on the move Speaker: Lars Ettarp, President of IFPA		
16.30 – 16.45	CLOSE OF SCIENTIFIC PROGRAM		

SUNDAY JUNE 28TH

IFPA informal member meeting
World Psoriasis Day Supporters meeting - Closed meeting





Looking to the future in Psoriasis

Visit us at our Booth
at the 2nd World Psoriasis
& Psoriatic Arthritis
Conference 2009



Registration

On-site registration

For on-site registration and/or questions, please contact the registration desk. The registration desk will open Wednesday June 24, 15.00-18.00. From 07.30 Thursday June 25 and will remain open all through the conference.

Registration Fees

Includes 25% VAT.

On site fee

Delegates	SEK 7500
Nurses and other health professionals	SEK 6875
Students* and IFPA Members	SEK 3440

Accompanying person fee (incl 25 %VAT) SEK 1875

*Student fee: Please include letter of introduction from your department chairman.

Delegate Fee Covers

Participation in conference sessions, satellite symposium, welcome reception, exhibition, afternoon coffees, poster sessions and the Stockholm City Hall reception and subsidized fee for the conference dinner.

Accompanying Person's Fee Covers

Participation in the welcome reception, poster session, the Stockholm City Hall reception and subsidized fee for the conference dinner.

Payment

Please contact the registration desk for any questions regarding your payment.

Accommodation

Please contact the registration desk for any questions regarding your hotel accommodation. The official conference hotels are: Scandic Norra Bantorget, Best Western Hotel Terminus, Hotell Lilla Rådmanen, Comfort Hotel Stockholm, Nordic Sea Hotel, Clarion Hotel Sign, Rica Hotel Kungsgatan, Rica Hotel Stockholm, Freys Hotel, Sheraton Stockholm, Hotel Tegnérilunden, Bentley Hotel

Important addresses

Conference & Exhibition Secretariat

MCI Stockholm Office
P.O. Box 6911
SE-102 39 Stockholm, Sweden
Phone: +46 8 5465 15 00
Fax: +46 8 5465 15 99
E-mail: psoriasis2009@mci-group.com

All correspondence to members of the Organizing Committee may be sent to the Conference secretariat for further distribution.

Program Information

Veronika Lindberg
Phone: +46 8 556 109 10
E-mail: veronika.lindberg@psa.se

IFPA Secretariat

Box 5173
SE-121 18 Johanneshov
SWEDEN
Phone: +46 8 556 109 14
Fax: +46 8 556 109 19
E-mail: ifpa@psa.se

Abstract Secretariat

Bruce F. Bebo Jr., Ph.D.
National Psoriasis Foundation, USA
E-mail: bbebo@psoriasis.org

Conference web site

www.ifpa-psa.org



Photo by Olof Holdar

$$\begin{array}{r} 365 \\ -4^* \\ \hline \end{array}$$

**That's 361 days to
focus on life... not psoriasis****

Introducing **the first in a new class** of biologics that selectively target IL-12 and IL-23 for the treatment of moderate-to-severe plaque psoriasis

Read more about Stelara® at www.stelara.se

Stelara (ustekinumab) Solution for injection, 45 mg/0.5ml. (Currently unavailable: 90 mg/1ml.) Rx.L04AC05 **Indication:** STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. **Packaging:** 1 vial, 45 mg/0.5 ml. **Subvention:** No. Stelara is filed for reimbursement in the Pharmaceutical Benefits Scheme in Sweden on 6 February 2009. **For full SPC and prices, go to www.fass.se**



Stelara[®]
(ustekinumab)



Photo by Richard Ryan

Social Program

- All events are available for delegates and accompanying persons and should have been prebooked on the registration form. For late bookings - please contact the registration desk for availability.
- A ticket is mandatory for entrance and will be handed out at the registration desk

Welcome Reception

Wednesday June 24 at 18:00 hrs

The welcome reception will take place at City Conference Centre/ Folkets Hus. Wine, soft drinks and snacks will be served. Included in the registration fee for delegates and accompanying guests only if marked on the registration form.

Reception, Stockholm City Hall

Thursday June 25 at 19:00 hrs

The City of Stockholm and the Stockholm County Council invite you to a buffet dinner at the Stockholm City Hall. Beautifully situated on the waterfront of Riddarfjärden in central Stockholm. The Stockholm City Hall is mostly famous for the Nobel Prize festivities, which take place in the Blue Hall every year on December 10.

Please bring the invitation card included in your delegate kit. Individual transport to and from the City Hall is located approximately within 15 minutes walking distance from the conference venue.

Conference Dinner


Friday June 26 at 19:30 hrs The Opera Terrace

Welcome to an unforgettable evening in one of Stockholm's most famous restaurants. The Opera Terrace, located on the second floor of Operakällaren, offers visitors a magnificent view of the Royal Palace, the Swedish Parliament and the surrounding waters through the panoramic windows. We will be served a first class three course conference dinner and enjoy delightful entertainment during the evening. Take this opportunity to network with fellow colleagues from all over the world.

Price: SEK 700

2ND WORLD PSORIASIS & PSORIATIC
ARTHRITIS CONFERENCE
SATELLITE SYMPOSIUM

Looking Deeper Into Psoriasis and Nail Disease



AGENDA

- 12:15 – 12:20 **Welcome and Introductions**
Jean-Hilaire Saurat, MD, Chair
Geneva University Hospital - Geneva, Switzerland
- 12:20 – 12:35 **Psoriasis and Systemic Inflammation:
Underdiagnosed Enthesopathy**
Giampiero Girolomoni, MD
University of Verona - Verona, Italy
- 12:35 – 12:50 **The Nail as a Skeletal Appendage—
Implications for Understanding
the Link Between Psoriasis and
Arthritis**
Dennis McGonagle, MB, FRCPI, PhD
University of Leeds - Leeds, United Kingdom
- 12:50 – 13:05 **Approach to Managing Patients
With Nail Involvement**
Alexandra Ogilvie, MD
Universität Erlangen - Erlangen, Germany
- 13:05 – 13:15 **Question-and-Answer Session**
Session Panel

Thursday, 25 June 2009
12:15 – 13:15

The Auditorium Norra Latin
Stockholm City
Conference Center
Stockholm, Sweden

*A light lunch will be set up in the Auditorium
Foyer from 12:00 – 12:15.*

This satellite symposium is sponsored by

 **Schering-Plough**

General information

in alphabetical order

Audio-visual facilities

All lecture halls will be equipped with PC computer projectors.

Badges

The delegates name badge will be provided at the registration desk. All delegates are requested to wear the badge throughout the Conference. Only badge holders will be admitted to the sessions.

Business hours & shopping

Shops are open between 10.00 and 18.00 hrs on weekdays and from 10.00 to 15.00 hrs on Saturdays. Shops in the City centre have extended opening hours, some even on Sundays between 12.00 and 16.00 hrs.

The main shopping streets in the centre of Stockholm are: Hamngatan, Biblioteksgatan, Drottninggatan and Västerlånggatan in the Old Town.

Certificate

You will find a Certificate of Attendance in your conference bag.

Climate and clothing

The average temperature in June is around 18°C (64°F)

CME Credits

EACCME and CME credit hours may be awarded for participation in the conference. An amount of 18 CME credit hours will be awarded for participation in the complete program. You can receive a CME certificate upon request at the registration desk.

Credit cards

International credit cards are accepted for payments in hotels, restaurants and shops.

Conference venue

The conference will be held at City Conference Centre/Folkets Hus and Norra Latin, between June 24-28, 2009. Address: Barnhusgatan 12-14. The conference venue is located in the centre of Stockholm, within walking distance from the Central Station. For further information please visit the conference venue web site. www.stoccc.se

Currency

The currency in Sweden is the Swedish krona, SEK.

1 Euro = 10,37 SEK

1 USD = 7,66 SEK

(Currency rate as per per May 2009.)

Currency calculation can be found on-line at www.x-rates.com

Exhibition

The Exhibiting companies are:

- Abbott
- EUROPSO
- Galderma Nordic
- H.Waldmann
- IFPA, World Psoriasis day
- Janssen Cilag
- LEO Pharma Sweden
- Psoriasis Association in Stockholm
- Quantel derma

- Saalmann
- Sandoz
- Schering-Plough
- Spa Smrdaky, Slovakia
- Tinefcon, Piramal Life Sciences
- Wyeth
- Wyeth Naked Truth

The Exhibition will be open for delegates on Thursday, June 25, 07.30-17.30, Friday 07.30-17.30 and Saturday 07.30-16.45.

Evaluation

After the conference you will receive an evaluation form by e-mail. Your opinion is very important for us and we appreciate that you take your time to fill it out.

Insurance

Neither the Conference Organizers or the Conference Secretariat accepts any liability for personal injuries sustained, or for loss or damage to property belonging to conference participants, either during or as a result of the conference.

All delegates are strongly advised to obtain their own insurance before travelling to the conference

Language

The official conference language is English. No simultaneous interpretation will be made.

Meals

Afternoon coffee will be served on the premises. Lunches are not included in the registration fee. However, there are several restaurants in the vicinity of the conference venue.

Press

Authorized members of the press are welcome to cover the 2nd World Psoriasis and Psoriatic Arthritis Conference. All press is welcome to register and use the on-line form. You will be asked to show your press identification at the venue.

Speaker's ready room

Please bring your PowerPoint presentation on a CD-rom or a USB memory stick and deliver it to the technician in the Speakers' ready room, room nr 401. This can be done between 8 am to 4 pm during the conference but at least 2 hours before your session starts.

Time zone

Sweden is 1 hours ahead of Greenwich Mean Time (GMT)

Tourist information

For tourist information on Stockholm and Sweden:

Tourist Center in 'Sweden House' (SverigeHuset) at Kungsträdgården.

E-mail: info@svb.stockholm.se

website: www.stockholmtown.com

Make hiding from plaque psoriasis part of the **PAST**



A clearer **FUTURE** can begin with **ENBREL**

When you choose **ENBREL**,
for your plaque psoriasis patients, you choose experience

- 16 years of collective clinical experience¹
- Over **1.6 million** patient-years of collective clinical experience¹
- Experience in over **105,000** plaque psoriasis and psoriatic arthritis patients¹
- Established safety profile in both adult and pediatric plaque psoriasis patients¹

**The #1-selling biologic worldwide
across its approved indications¹**



Indications

ENBREL is indicated for the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

ENBREL is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

ENBREL is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. ENBREL has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

Important Safety Information

Serious infections, including tuberculosis, and sepsis have been reported. Some of these infections have been fatal.

Do not start ENBREL in the presence of allergy to ENBREL or its components.

There have been rare reports of CNS demyelinating disorders, although the causal relationship to ENBREL remains unclear.

For more information, please refer to the ENBREL Summary of Product Characteristics.

Reference: 1. Data on file, Amgen Inc., Thousand Oaks, CA.

Rare cases of pancytopenia, and very rare cases of aplastic anemia, some fatal, have been reported in patients treated with ENBREL. Exercise caution in patients who have a previous history of significant hematologic abnormalities. Although the causal relationship to ENBREL remains unclear, advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. If significant hematologic abnormalities are confirmed, discontinue ENBREL.

Reports of malignancies affecting various sites have been received in the postmarketing period. Effects of ENBREL therapy on the development or course of infection and malignancy are unknown. In clinical trials of TNF antagonists, more cases of lymphoma were seen compared to control patients; however, the risk of lymphoma may be higher in RA patients.

Before initiation of therapy with ENBREL, any patient at increased risk for tuberculosis (TB) should be evaluated for active or latent infection. Prophylaxis of latent TB infection should be initiated prior to therapy with ENBREL. Applicable local guidelines should be consulted.

Reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus who are receiving anti-TNF agents, including ENBREL, has been reported. Patients at risk for HBV infection should be evaluated for prior evidence of the virus before initiating anti-TNF therapy. Although a causal relationship has not been established for ENBREL, caution should be exercised when administering ENBREL for patients identified as carriers for HBV.

There have been reports of worsening of hepatitis C in patients receiving ENBREL, although a causal relationship with ENBREL has not been established.



Photo by Richard Ryan

Stockholm and Sweden

Welcome to Stockholm, the Royal Capital of Sweden. Discover a city like no other - a city built on 14 islands, where you are never far from the water. Well-preserved medieval buildings stand alongside modern architecture. Stockholm is also home of the Nobel Prize. And just outside the city, the archipelago of 24 000 islands is waiting to be explored.

Stockholm is a city of contrasts - water and islands, history and innovation, small town and big city, short winter days and long, light summer nights - with a dazzling array of impressions. Thanks to the city's compact size, you can see and do most things in a short space of time - which makes it a perfect destination for city breaks or longer stays, all the year round.

Discover a city of contrasts. Go back 750 years in time and feel the medieval atmosphere of the Old Town "Gamla Stan" as you wander through the narrow streets. Stockholm has got history - but also the latest in fashion and IT. The trendy Stockholmers are often used as a test market by international companies, as they are quick to pick up on the latest trends.

Stockholm is one third water, one third green belt and one third city. The island of Djurgården, the worlds first National City Park, is only a short walk from the pulse of the inner city.

Stockholm is very well positioned with most of Europe within three hours reach. It is a genuine meeting point in every respect and an increasingly important hub for flights to major destinations in the Baltic Sea Region, European Union and the expansive global community.

Sweden is the fourth largest country in Europe. Nearly 100 000 lakes dot the Swedish countryside, which is relatively flat apart from a long mountain chain in the north. There are thousands of islands off the jagged coast and the warm Gulf Stream in the Atlantic provides Sweden with a milder climate than other countries situated equally far north. Stockholm, the capital, is at almost the same latitude as southern Greenland but has an average temperature of aprox. +18C (64F) in June. Above the arctic circle, you can also experience the midnight sun, when the sun never sets.

Psoriasis: the naked truth



"I wanted to show off my body just as it is, without any shame, and to show that even with psoriasis we can be beautiful."

Maria Javiera, 26, Chile

Photographic Exhibition by Ralf Tooten

Psoriasis: The Naked Truth is a pan-European educational programme to raise awareness of the physical and emotional impact of psoriasis. The centrepiece of *Psoriasis: The Naked Truth* is a photo exhibit that captures the experience of living with psoriasis through photography and personal stories.

Abstract Titles

Genetics, genomics and proteomics

1. KIR genes in Portuguese patients with psoriasis vulgaris

Tiago Torres¹, Patrícia Rodrigues², Clara Pereira², Paulo Costa², Berta Martins², Manuela Selores²
¹CHP-HSA, ²ICBAS-UP, ³Dermatology Department CHP-HSA, Portugal

2. A genome-wide linkage scan of familial psoriasis: linkage to chromosome 2

Myriam Ammar¹, Chiraz Bouchlaka-Souissi¹, Ines Zraa², Nejib Doss³, Cindy Helms², Mourad Mokni², Anne Bowcock⁴
¹Faculty of Sciences of Tunis, ²LaRabta Hospital, ³Military Hospital, Tunisia ⁴Washington University in Saint Louis, United States ⁵La Rabta Hospital, Tunisia ⁶Washington University - Saint Louis, United States

3. Heritability in psoriatic arthritis in five generations. The Reykjavik psoriatic arthritis study.

Bjorn Gudbjornsson¹, Thorvardur Jon Love², Ari Karason³
¹University Hospital, Iceland ²Harvard University, Boston, United States ³deCODE Genetics, Iceland

4. The molecular profile of psoriatic skin in responders to ustekinumab or etanercept following twelve weeks of treatment: Results from the ACCEPT Trial

James Krueger¹, Katherine Li², Frédéric Baribaud², Mayte Suarez-Farinas¹, Carrie Brodmerkel²
¹Rockefeller University, ²Centocor Research and Development, Inc., United States

5. Association between the PTPN22 +1858 C/T polymorphism and Psoriatic Arthritis

Kristina Juneblad¹, Maritn Johansson², Solbritt Rantapää Dahlqvist², Gerd-marie Alenius²
¹Dpt. of Rheumatology, Umeå, Sweden

6. Simple and rapid screening for HLA-Cw*06 in psoriatic patients from Poland

Aneta Szczerkowski Dobosz¹, Aneta Szczerkowska Dobosz¹, Krzysztof Rebala¹, Joanna Wysocka¹
¹Medical University of Gdansk, Poland

7. A Quantitative analysis of digitopalmar dermatoglyphics in 400 Psoriasis and Psoriatic arthritis patients from Croatia

Miljenko Cvjeticanin¹, Jajic Zrinka², Jajic Ivo²
¹Zagreb Rehabilitation Center, ²University Department of Physical Medici, Croatia

8. HLA and KIR gene frequency in a multiethnic psoriasis and psoriatic arthritis patients.

Sueli Carneiro¹, Flavia Cassia¹, Danielli Cristina Oliveira², Maria Teresa Marques², Luis Cristovão Porto², Carolina Portela¹, Marcia Ramos-e-Silva¹
¹Federal University of Rio de Janeiro, ²State University of Rio de Janeiro, Brazil

Pathophysiology and Immunobiology

9. Seric and synovial fluid values of cytokines in psoriasis arthritis and rheumatoid arthritis patients

Caius Solovan¹, Camelia Ciaci¹
¹University of Medicine and Pharmacy, ²West University, Immunology, Arad, Romania

10. Th-17 cells in psoriatic disease: Studies in developing psoriatic lesions and psoriatic arthritis

Siba Raychaudhuri¹, Smriti Raychaudhuri²
¹University of California, Davis, ²VA Medical Center Sacramento, United States

11. SCID mouse-human skin chimera: A unique animal model for novel drug discovery of psoriasis and autoimmune diseases.

Siba Raychaudhuri¹, Smriti Raychaudhuri²
12. Characterization of the inflammatory microenvironment during acute guttate psoriasis in blood and skin.
Liv Eidsmo¹, Mona Ståhle¹
¹Karolinska Institutet, Sweden

13. Visualisation of Langerin-expressing cells in the skin during acute and guttate psoriasis.

Milena Macitelli¹, Mona Ståhle¹, Liv Eidsmo¹
¹Karolinska Institutet, Sweden

14. The role of human microRNA-125b in psoriasis

Ning Xu¹, Tianling Wei¹, Ahmad Pazirandeh¹, Mona Ståhle¹, Enikő Sonkoly¹, Andor Pivarcsi¹
¹Karolinska Institutet, Sweden

15. Protein kinase C-dependent upregulation of miR-203 during keratinocyte differentiation

Enikő Sonkoly¹, Enikő Sonkoly¹, Tianling Wei¹, Elizabeth Pavez Lorie², Hans Törmä², Mona Ståhle², Andor Pivarcsi¹
¹Karolinska Institutet, ²Uppsala University, Sweden

16. Atineutrophil Cytoplasmic Antibodies - serologic marker in Psoriatic Arthritis

Hanna Przepiera-bedzak¹, Iwona Brzosko¹, Katarzyna Fischer¹, Marek Brzosko¹
¹Pomeranian Medical University, Poland

17. The potential role of angiogenic cytokines: VEGF, EGF, FGFb and FGfa in psoriatic arthritis

Hanna Przepiera-bedzak¹, Iwona Brzosko¹, Katarzyna Fischer¹, Marek Brzosko¹
¹Pomeranian Medical University, Poland

18. The expression of microRNA 203 during human skin morphogenesis

Tianling Wei¹, Törmä Hans², Hao Li², Andor Pivarcsi¹, Mona Ståhle¹, Enikő Sonkoly¹
¹Karolinska Institutet, ²Uppsala University Hospital, Sweden

19. NF-κB- and STAT3-dependent cytokine production by circulating CCR6+CD4+ Th17 cells is increased in psoriasis

Andrew Blauvelt¹, Shinji Kagami¹, Heather Rizzo¹, Jennifer Lee¹, Yoshinobu Koguchi¹, Andrew Blauvelt¹
¹Oregon Health & Science University, United States

20. Synovial tissue and psoriatic lesional skin show marked interleukin-20 expression in patients with psoriatic arthritis.

Christina Jonckheere¹, Arno Van Kuijk¹, Cristina Lebre¹, Maartje Boumans¹, Danielle Gerlag¹, Paul-Peter Tak¹
¹AMC, Netherlands

21. Neuronal changes in psoriasis exacerbation

Husameldin El-Nour¹, Alexander Santos¹, Malin Nordin¹, Pontus Jonsson¹, Margreta Svensson², Klas Nordlind¹, Mats Berg³
¹Karolinska Institutet, ²Private practitioner, ³Uppsala Academic Hospital, Sweden

22. The impact of tonsillectomy on patients with chronic psoriasis

Helgi Valdimarsson¹, Ragna Thorleifsdottir¹, Sigrun Sigurdardottir², Jon Olafsson³, Bardur Sigurgeirsson³, Hannes Petersen⁴, Andrew Johnston⁵
¹Landspítali University Hospital, ²PhD student, ³Dermatologist, ⁴ENT surgeon, Iceland ⁵Assistant Professor, United States

Epidemiology

23. Body weight and smoking associates with onset of plaque psoriasis: a population based case-control study.

Katarina Wolk¹, Lotus Mallbris¹, Per Larsson¹, Andreas Rosenblad², Eva Vingård², Mona Ståhle¹
¹Karolinska Institutet, ²Uppsala University, Sweden

24. Prevalence of articular involvement in patients with psoriasis

Rieke Driessen¹, Delia Diaconu¹, Rieke Driessen¹, Peter Van De Kerkhof¹, Piet Van Riel¹, Jaap Franssen¹, Elke De Jong¹
¹Radboud University Medical Centre, Netherlands

25. What information do patients with Psoriatic Arthritis seek about their condition?

Charlotte Cavill¹, Neil Mchugh², Nicola Waldron², Ellie Korendowych²
¹Bath Institute for Rheumatic Diseases, ²RNHRD, United Kingdom

26. Increased Risk of Psychiatric Disorders in a Pediatric Population With Psoriasis

Alexa B Kimball¹, Annie Guérin², Andrew P Yu², Eric Q Wu², Shiraz R Gupta³, Yanjun Bao³, Parvez M Mulani³
¹Harvard Medical School, ²Analysis Group, Inc., ³Abbott Laboratories, United States

27. The characteristics of a psoriatic arthritis (PsA) cohort in Newfoundland, Canada with an early diseases subset.

Majed Khraishi¹, Sarah Maclaughlin¹, Gerry Mugford¹, Karen White²
¹Memorial University of Newfoundland, ²Nexus Clinical Research, Canada

28. Mortality in Psoriatic Arthritis - A UK Perspective

Caitriona Buckley¹, Charlotte Cavill¹, Gordon Taylor², Hazel Kay¹, Nicola Waldron¹, Eleanor Korendowych¹, Neil Mchugh¹
¹RNHRD, ²University of Bath, United Kingdom

29. Psoriasis treatment patterns of dermatologists in Northeast Ohio.

I Grozdev¹, L Cao¹, K Kavlick¹, Rt Brodell¹, En Mostow¹, Nj Korman¹
¹Murdough Family Center for Psoriasis, United States

30. Psoriasis patient care at two German university hospitals - results of an epidemiological review

Stefanie Heimann¹, Inka Hillers², Andreas Colsmann³, Michael Sticherling³
¹University Hospitals of Erlangen, ²Univ.Hautklinik Leipzig, ³Department of Dermatology Erlangen, Germany

31. Psoriatic arthritis prevalence in Mexican patients with psoriasis attending a third level dermatological institute.

Jose Fernando Barba-Gomez¹, Elizabeth Guevara-Gutierrez¹, Miroslava Zolano-Orozco¹, Gabriela Briseño-Rodríguez¹, Guadalupe Villanueva-Quintero¹, Alberto Tlacuilo-Parra², Sergio Gutierrez-Ureña¹
¹Instituto Dermatológico de Jalisco, ²UMAE Hospital de Pediatría IMSS, Mexico

32. Analysis of Factors associated with Obesity in Psoriatic Arthritis

Allen Anandarajah¹, Christopher Ritchlin¹
¹University of Rochester Medical Center, United States

Comorbidities

33. Comorbidities in Psoriasis

Nora Kogan¹, Rosana Veira¹, Elena Chaparro¹, Alejandra Crespo¹, Simon Gusic¹, Mercedes Hassan¹
¹Argentina

34. Prevalence of psychiatric disorders in psoriatic patients: A survey study.

Ramin Taheri¹, Behnaz Behnam¹
¹Iran

35. Psoriasis and comorbidities during a two years evaluation

Caius Solovan¹, Esther Baiduc¹
¹University of Medicine and Pharmacy, Romania

36. Cardiovascular comorbidity in patients with psoriasis

Javorka Delic¹, Javorka Delic², Vesna Vlahovic², Nada Pantic²
¹City Institute for Dermatology, ²Serbia

37. Adalimumab induced psoriasis of the scalp resulting in extensive non-scarring and scarring alopecia

Laila El Shabrawi-Caelen¹, Michelangelo Laplaca², Colombina Vincenzi², Thomas Haidn¹, Robert Müllegger¹, Antonella Tosti²
¹Austria ²Italy

38. Rheological properties of blood as a marker of inflammation and cardiovascular risk in psoriatic arthritis.

Tatiana Korotaveva¹, Elena Loginova¹, Diana Novikova¹, Lev Denisov¹, Nadezhda Klimova¹, Elena Alexandrova¹, Evgeniy Nasonov¹
¹Institute of Rheumatology of RAMS, Russian Federation

39. Comorbidity Prevalence in Psoriasis Patients: A Meta-Analysis

Parvez Mulani¹, Annie Guérin², Andrew P Yu², Eric Q Wu², Shiraz R Gupta³, Yanjun Bao³, Ulrich Mrowietz³
¹Abbott Laboratories, ²Analysis Group, Inc., United States ³Campus Kiel, Germany

40. Co-morbidities in a psoriatic arthritis cohort.

Majed Khraishi¹, Sarah Maclaughlin¹, Gerry Mugford¹, Karen White²
¹Memorial University of Newfoundland, ²Nexus Clinical Research, Canada

41. Metabolic syndrome at psoriasis onset and at long-term follow-up of psoriasis: A prospective cohort study

Lotus Mallbris¹, Lotus Mallbris¹, Katarina Wolk¹, Petra Kjellman¹, Tobias Nordquist², Mona Ståhle¹
¹Karolinska Institutet, ²Uppsala University, Sweden

42. Inflammation: A pivotal link between Psoriatic Arthritis and Atherosclerosis

Anna Abou-Raya¹, Suzan Abou-Raya¹
¹University of Alexandria, Egypt

43. LIPID PATTERN IN PSORIATIC PATIENTS IN A BRAZILIAN POPULATION OBSERVED IN AN UNIVERSITY HOSPITAL
Sueli Carneiro¹, Fabiola Pereira², Marcelo Brollo³, Gustavo Verardino³, Mario Chaves³, Alessandra Drummond¹, Marcia Ramos-e-silva⁴

¹Federal University of Rio de Janeiro, ²State University of Rio de Janeiro, ³State University of R, Brazil

Clinical Research and Therapeutics

44. Daivobet in the tropical treatment of psoriasis vulgaris.

Iryna Voznyak¹, Tatyana Svyatenko²
¹Danylo Halytsky Lviv National Medical Un, ²Dniepropetrovsk State Medical Academy, Ukraine

45. Withdrawn

46. Comparing Attrition for the Biologic Therapies: Biologic Survival

Ronald Vender¹, Kristen Noiles²
¹Dermatials Research, ²McMaster University, Canada

47. Disease duration of psoriatic arthritis is an important risk factor for reduced heart rate variability.

Diana Novikova¹, Tatiana Korotaeva², Elena Loginova³, Alexander Novikov³, Elena Alexandrova³, Evelina Mach³, Eugeny Nasonov²
¹Institute of Rheumatology of RAMS, ²Rheumatology, ³Clinical research, Russian Federation

48. Infliximab in the management of psoriasis of patients previously treated with other biologic agents.

Theognosia Vergou¹, Aikaterini-Evangelia Moustou¹, Paraskevi Tseke¹, Alexander Stratigos¹, Christina Antoniou¹
¹A. SYGROS HOSPITAL OF ATHENS, Greece

49. A sensor-based Excimer-Laser therapy for Psoriasis vulgaris

Peter Weisenseel¹, Sonja Molin², Oleksander Kovnerystyy², Joerg C. Prinz², Florian Klempf³, Peter Kaudewitz²
¹Ludwig-Maximilians-University, ²Department of Dermatology, LMU Munich, ³Bavarian Laser Centre, Erlangen, Germany

50. Clinical analysis of 225 cases of generalized pustular psoriasis

Xu Fang¹, Jun Zhou¹, Qiong Huang¹
¹Huashan Hospital, Fudan University, China

51. Efficacy and safety of efalizumab, etanercept and infliximab in psoriasis: Our experience

Ahmet Akar¹, Mustafa Tunca², Ercan Caliskan², Erol Koc², Zafer Kurumlu²
¹GATA, ²GATA Dermatology, Turkey

52. Achieving minimal disease activity (MDA) criteria decreases progression of joint damages in PSA.

Laura Coates¹, Catherine Schentag², Ker-Ai Lee³, Vinod Chandran², Richard Cook², Dafna Gladman²
¹University of Leeds, United Kingdom ²Toronto Western Hospital, ³University of Waterloo, Canada

53. Videodermoscopy and in vivo reflectance confocal microscopy in plaque psoriasis.

Lidia Rudnicka¹, Olszewska Malgorzata², Kardynal Agnieszka³, Kurzeja Marta³, Warszawik Olga³
¹CSK MSWiA, ²Warsaw Medical University, Poland ³CSK MSWiA,

54. Experience of topical therapy in treatment of psoriasis vulgaris.

Yuriy Andrashko¹, Hennadiy Atsaturov², Oleg Nadashkevich²
¹Uzhgorod National University, ²Department of dermatovenereology, Ukraine

55. Efficacy of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis patients with baseline C-reactive protein >=0.4 vs <0.4 mg/dL: results of a post hoc analysis of data from a phase 2, randomized, double-blind, placebo-controlled study

Alice Gottlieb¹, Alan Menter², Alan Mendelsohn³, Young-kaung Shen³, Shu Li³, Arthur Kavanaugh⁴
¹Tufts Medical Center, ²Baylor Research Institute, ³Centocor Research and Development, Inc., ⁴University of California San Diego, United States

56. TNF-alpha blockers in the treatment of early psoriatic arthritis: An observational follow-up study.

Mariangela Atteno¹, Salvatore D'angelo², Ennio Lubrano³, Giuseppe Provenzano⁴, Ignazio Olivieri⁵, Raffaele Scarpa⁶
¹University of Naples Federico II, ²Rheumatology Department of Lucania, ³Fondazione Maugeri, IRCCS, Telese (BN), ⁴Rheumatology Unit, AO Villa Sofia (PA), ⁵Department of Lucania, ⁶University Federico II Naples, Italy

57. Effectiveness of etanercept in axial psoriatic arthritis.

Ennio Lubrano¹, Antonio Spadaro², Antonio Marchesoni³, Raffaele Scarpa⁴, Salvatore D'angelo⁵, Mariagrazia Cat-

anoso⁶, Carlo Salvarani⁶
Fondazione Maugeri, IRCCS, Telese (BN), ²University of Rome La Sapienza, ³Gaetano Pini Hospital Milan, ⁴University of Naples Federico II, ⁵Department of Lucania Potenza, ⁶Arcispedale S.Maria Nuova Reggio Emilia, Italy

58. Outcome Data on Cohort of PsA Patients on Biologic Therapy

Nicola Waldron¹, Charlotte Cavill¹, Neil Mchugh¹, Eleanor Korendowych¹
¹RNHRD, United Kingdom

59. Combination of Skin and Joint Outcomes With Etanercept in Psoriatic Arthritis

Joerg Prinz¹, Olivier Brocq², Diamant Thaci³, Robert Boggs⁴, Charles Molta⁴, Debbie Robertson⁴, Bruce Freundlich⁴
¹University of Munich, Germany ²Princesse Grace Hospital of Monaco, Monaco ³Johann Wolfgang Goethe-University, Germany ⁴Wyeth, United States

60. Influence of Body Mass Index (BMI) on Efficacy of Etanercept in Psoriasis: The PRESTA Study

Pascal Joly¹, Bruce Kirkham², Debbie Robertson³, Ronald Pedersen³, Charles Molta³, Bruce Freundlich³, Jeffrey Melin³
¹Hôpital Charles Nicolle, France ²Guy's & St Thomas' Hospital, United Kingdom ³Wyeth, United States

61. Efficacy and safety of the new betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis

Luigi Naldi¹, Lasse Braathen², Andrzej Kaszuba³, Jean-paul Ortonne⁴
¹Centro Studi GISED, Italy ²Dermatological University Clinic, Bern, Switzerland ³Department of Dermatology, MMA, Łódź, Poland ⁴Dermatologie, Hôp. de l'Archev, Nice, France

62. Spondylitis in Patients with Psoriatic Arthritis

Vinod Chandran¹, David Tolusso², Catherine Schentag³, Richard Cook⁴, Dafna Gladman¹
¹University of Toronto, ²University of Waterloo, ³Toronto Western Hospital, ⁴University of Waterloo, Canada

63. BELIEVE Study Results: Adalimumab Plus Calcipotriol/Betamethasone Is Effective and Safe in Psoriasis

Diamant Thaci¹, Jean-Paul Ortonne², Pierre-dominique Ghislain³, Per Sproege⁴, Kristina Unnebrink⁵, Hartmut Kupper⁵
¹Goethe University Frankfurt, Germany ²University of Nice, ³UCL Saint-Luc, France ⁴LEO Pharmaceutical Products Ltd. A/S, Denmark ⁵Abbott GmbH & Co. KG, Germany

64. Experience with Rifampicin in the treatment of psoriasis

Ivan Grozdev¹, Ivan Grozdev², Jana Kazandjieva², Nikolai Tsankov²
¹Medical faculty, Sofia, Bulgaria

65. Predictors of response to intra-articular steroid injection in psoriatic arthritis.

Lih Eder¹, Vinod Chandran¹, Catherine T Schentag¹, Ker-Ai Lee², Richard J. Cook², Dafna D. Gladman¹
¹Toronto Western Hospital, ²University of Waterloo, Canada

66. Efficacy and Safety of Ustekinumab in Patients with Moderate-to-Severe Psoriasis and Concomitant Psoriatic Arthritis: Result from Phase 3 Randomized Clinical Trials

Craig Leonardi¹, Kim Papp², Rod Kynnetz², Philippe Szapary⁴, Shu Li⁴, Newman Yeilding⁴, Kristian Reich⁵
¹Central Dermatology, United States ²Probit Medical Research, ³Ultranova Skincare, Canada ⁴Centocor Research and Development, Inc., United States ⁵Dermatologikum Hamburg, Germany

67. The pattern of disability in a real life psoriatic arthritis cohort.

Maclaughlin Sarah¹, Majed Khraishi², Gerry Mugford², Karen White²
¹Nexus Clinical Research, ²Memorial University of Newfoundland, Canada

68. CAN-EASE: Canadian assessment of patient outcomes and effectiveness of enbrel in psoriasis.

Ronald Vender¹, Sheetal Sapra², Martin Gilbert³, Richard Haydey⁴, Robert Termaine⁵, Charles Lynde⁶, Vincent Ho⁷
¹Dermatials Research, ²Institute of Cosmetic and Laser Surgery, ³Centre Recherche Clinique, ⁴Winnipeg Clinic, ⁵MSHJ Research Associates, ⁶LyndermResearch Inc, ⁷University Of British Columbia, Canada

69. REPARÉ: Interim analysis of Canadian phase 4 study of etanercept in psoriatic arthritis.

Dafna Gladman¹, Claire Bombardier², Carter Thorne³, Paul Haraoui⁴, Majed Khraishi⁵, Proton Rahman⁵, William

Bensen⁶
¹Toronto Western Hospital, ²University Health Network, ³Southlake Regional Health Centre, ⁴Institut de Rhumatologie de Montreal, ⁵St. Clare's Mercy Hospital, ⁶McMaster University, Canada

70. Arterial stiffness in Psoriatic Arthritis (PsA) patients.

Luisa Costa¹, Lanfranco D'elia¹, Francesco Caso¹, Rosario Peluso¹, Mariangela Atteno¹, Pasquale Strazzullo¹, Raffaele Scarpa¹
¹University Federico II, Italy

71. Case documentation of the treatment of psoriasis vulgaris with a fixed combination of calcipotriol and betamethasone dipropionate

Frank Bachmann¹, Durdana Groß¹, Antje Schumacher¹, Jürgen Schaaß², Sandra Philipp¹
¹University Medicine Berlin, Charité, ²Verlagsgesellschaft mbH, Germany

72. Effectiveness of Leflunomide in Psoriatic Joint and Skin Disease: Results from a non-interventional Study of Psoriatic Arthritis

Frank Behrens¹, Karel Pavelka², Jiri Stolfa², A. Sipek-Dolnicar³, Harald Burkhardt⁴
¹Goethe University, Germany ²Institute of Rheumatology Prague, Czech Republic ³University Medical Center Ljubljana, Slovenia ⁴Goethe University, Frankfurt, Germany

73. Efalizumab-induced aseptic meningitis

Wolfgang Weger¹, Wolfgang Weger¹, Silvia Koller¹, Binder Barbara¹, Salmhofer Wolfgang¹
¹Medical University of Graz, Austria

74. The increasing efficiency of balneophototherapy with Halobacterium halobium as exogenous photosensibilizer.

Yuriy Andrashko¹, Alexandr Litus¹, Irina Sharkan¹, Bohdan Lytvynenko²
¹Uzhgorod National University, ²Ukrainian Medical and Dental Academy, Ukraine

75. Methotrexate and hepatic toxicity in psoriatic arthritis and rheumatoid arthritis.

Carla Matias¹, Anabela Barcelos²
¹Internal Medicine - HIP, ²Rheumatology - HIP, Portugal

76. Usage of new localized UVB source in the treatment of psoriasis.

Bohdan Lytvynenko¹, Yuriy Andrashko², Aleksandr Litus², Irina Sharkan², Kuzma Khobzey³
¹Uzhgorod National University, ²Institute of Psoriasis, Ukraine

77. Isotretinoin in association with phototherapy – our experience in psoriatic women.

Joana Dias Coelho¹, Filipa Diamantino¹, Fernando Guerra¹, Margarida Apetato¹
¹Centro Hospitalar de Lisboa Central, Portugal

78. Topical psoralen-ultraviolet A therapy for palmo-plantar psoriasis: a 12-year retrospective analysis

Filipa Diamantino¹, Joana Dias Coelho¹, Fernando Guerra¹, Margarida Apetato¹
¹Hospital dos Capuchos - CHLC, Portugal

79. Pentraxin 3: A Novel Marker of Inflammation in Psoriatic Arthritis Patients

Suzan Abou-Raya¹, Anna Abou-Raya¹, Madihag Helmi²
¹University of Alexandria, ²Medical Research Institute, Egypt

80. TNF-Alpha, IL-6, IL-17 and IL-18 in Psoriasis and Psoriatic arthritis: Are they reliable disease severity and disease activity biomarkers?

Suzan Abou-Raya¹, Anna Abou-Raya¹, Madihag Helmi²
¹University of Alexandria, ²Medical Research Institute, Egypt

81. The Weekly versus daily administration of oral methotrexate (MTX) for the treatment of plaque psoriasis a randomized controlled clinical trial.

Mohammad Radmanesh¹, Zahra-beigum Moosavi¹, Behnam Rafiei², Niloofer Sina³, Nahid Bagheri⁴
¹Jondishapour University, ²GP, ³Private practice, ⁴Private practice, Iran

82. The self administered Psoriatic Arthritis Screening Questionnaire (PASQ) is a sensitive tool in detecting early and established psoriatic arthritis patients

Majed Khraishi¹, Ian Landells²
¹Memorial University of Newfoundland, ²Nexus Clinical research and Memorial Uni, Canada

83. Detection of psoriasis patients with a patient-questionnaire from dermatology outpatient clinics in Germany

Peter Härle¹, Wolfgang Hartung², Ulf Müller-ladner³, Ingo

Turner⁴, Thomas Vogt⁵, Martin Fleck²
¹Katholisches Klinikum Mainz, ²Asklepios Rheumatology Clinic Bad Abbach, ³Kerckhoff-Clinic, Bad Nauheim, ⁴Kerckhoff Clinic, Bad Nauheim, ⁵Dermatology, University of Regensburg, Germany

84. Lattice system physician's global assessment is validated for assessing psoriasis.

Charles Ellis¹
¹University of Michigan Medical School, United States

Biomarkers and Imaging

85. Clinical forms of psoriatic arthritis and immunogenic determinants at patients in Republic of Moldova.

Eugeniu Russu¹, Liliana Groppa², Constantin Babiu³, Gheorghe Muset², Natalia Isac², Grigore Moraru²
¹State Medical University, ²Republic Of Moldavia

86. Low Field MRI with prototype finger coil for studying nail unit in Psoriatic Arthritis (PsA) patients.

Ernesto Soscia¹, Marco Amedeo Cimmino², Mariangela Atteno¹, Salvatore Iervolino¹, Antonio Del Puente¹, Marco Salvatore¹, Raffaele Scarpa¹
¹University Federico II, ²University of Genova, Italy

87. Whole body magnetic resonance imaging of peripheral and axial joints in patients with psoriatic arthritis

Susanne Juhl Pedersen¹, Jakob Møller², Inge Juul Sørensen², Mikkel Østergaard⁴
¹Gentofte and Herlev University Hospitals, ²Dep. of radiology, Herlev Hospital, ³Dep. of rheumatology, Hvidovre Hospital, ⁴Rheumatology, Hvidovre Gentofte Hospital, Denmark

88. Accumulation of altered aspartyl residues in erythrocyte membrane proteins from psoriasis patients.

Anna Balato¹, Patrizia Galletti², Nicola Balato¹, Stefania D'Angelo³, Filomena Flora², Lucia Gallo¹, Vincenzo Zappia³
¹University of Naples Federico II, ²Second University of Naples, Italy

89. Effect of biological therapy on plasma levels of MCP-1 in plaque psoriasis patients.

Serena Lembo¹, Maria Luigia De Bonis², Marianna Raimo², Serena La Bella¹, Rosanna Capasso², Diego Ingresso², Fabio Ayala¹
¹University of Naples Federico II, ²Second University of Naples, Italy

90. Dendritic Cell-Surface Transmembrane Protein (DC-STAMP) is a biomarker for osteoclast precursors in psoriatic arthritis.

Yahui Grace Chiu¹, Kofi Mensah², Changyong Feng², Edward Schwarz², Christopher Ritchlin²
¹University of Rochester, ²United States

Quality of Life

91. Quality of life in psoriatic patients from Buenos Aires, Argentina.

Ignacio Dei-cas¹, César Lagodin², Milagros Branciforte², Liliana Cuellar², Paula Tordoya², Miguel Allevato²
¹Hospital de Clínicas José de San Martín, ²Argentina

92. Psoriasis and quality of life - Student's Health Institute in Belgrade results

Lida Tomic Radovanovic¹, Alma Krdzovic Marjanovic², Jasna Czurda Potic²
¹Student's Health Institute in Belgrade, ²Serbia

93. The effects of climate therapy on people with psoriatic arthritis

Sonja Bäckman¹, Sonja Bäckman¹, Heikki Hurri², Hannu Kautiainen², Leena Koulu², Leena Paimela², Mirja-Liisa Rontu¹
¹The Finnish Psoriasis Association, ²Orton Foundation, ³Turku University Hospital, Finland

94. Impact of Adalimumab on Quality of Life and Depression in Psoriasis Patients: Results From PRIDE

Nick Bansback¹, Kim Papp², Charles Lynde³, Wei Zhang¹, Hong Qian¹, Marie-josée Martel⁴, Henrique Teixeira⁴
¹Centre for Health Eval & Outcomes Sci, ²Probity Medical Research, ³Lynde Centre for Dermatology, ⁴Abbott Laboratories, Canada

95. Psycho-social implications of psoriasis

Mirona Ioana Marcu¹, Caius Solovan²
¹Ministry of the Interior, ²Univ. Of Medicine and Pharmacy Timisoara, Romania

96. Quality of life assessments that measure a single point in time may underestimate lifetime impact

Elizabeth Seidler¹, Alexa Kimball¹
¹Massachusetts General Hospital, United States

97. Depressive Symptoms and Quality of Life in Psoriatic Patients with Different Lesion Localizations

Konrad Janowski¹, Stanislaw Studen¹, Aldona Pietrzak², Grazyna Chodorowska², Dorota Krasowska², Ilona Gradus¹, Lukasz Kaczmarek¹
¹Catholic University of Lublin, ²Medical University of Lublin, Poland

98. Coping Strategies and Disease-Related Appraisals in Psoriatic Patients with Different Lesion Localizations

Konrad Janowski¹, Stanislaw Studen¹
¹Catholic University of Lublin, Poland

99. Development of a composite Disease Activity score in Psoriatic Arthritis.

Aizad Mumtaz¹, Phil Gallagher², Brian Kirby², Laura C.Coates³, Robin Waxman³, Phillip Helliwell³, Oliver Fitzgerald⁴
¹St Vincents University Hospital Dublin, ²St Vincents University Hospital, Ireland ³University of Leeds, United Kingdom ⁴St Vincent University Hospital, Ireland

100. PATIENT PARTICIPATION IN RESEARCH, A SWEDISH MODEL

Nina Hemmestad Linderfeldt¹
¹Sweden

101. Psoriasis social network web site www.psoriasis-patients.com

Richard Thomas¹, Roman Bond²
¹skincareguide.com, ²Canada
PSORIASIS PATIENTS.COM

102. Evaluation of the quality of life in 200 Brazilian psoriatic patients.

Sueli Carneiro¹, Maria Augusta Japiassú¹, Bruna Darcier¹, Fernanda Torres¹, Mario Chaves², Gustavo Verardino², Marcia Ramos-e-Silva¹
¹Federal University of Rio de Janeiro, ²State University of Rio de Janeiro, Brazil

Clinical Cases

103. Borreliosis mimicking lupus-like syndrome during infliximab treatment

Sonja Molin¹, Jörg C. Prinz¹
¹Ludwig-Maximilians-University, Germany

104. Development of viral warts in a patient receiving TNF- inhibitor etanercept

Tiago Torres¹, Gloria Velho², Madalena Sanches², Manuela Selores²
¹CHP-HSA, ²Dermatology Department CHP-HSA, Portugal

105. Effectiveness of Treatment with Infliximab in a subject suffering from psoriasis and personality disorder borderline

Rossella Filippetti¹
¹uoc dermatologico ospedale frascati roma, Italy

106. Psoriasis vulgaris and ektkracutaneous sarcoidosis: A case report

Mustafa Tunca¹, Ahmet Akar², Hakan Erbil², Ibrahim Ozmen², Erol Koc², Seyfettin Gumus²
¹Gulhane Military Medical Academy, ²GATA Dermatology, ³GATA Chest and Tuberculosis, Turkey

107. Immunophenotype of the inflammatory infiltrate and epidermis cellular regeneration in the psoriatic papule

Vitaly Okhlopkov¹, Olga Pravdina²
¹The Omsk State Medical Academy, ²Russian Federation

108. Reasonableness for systemic immunosuppressive drugs administration in treatment of patients with psoriasis

Vitaly Okhlopkov¹, Elena Zubareva¹
¹the Omsk State Medical Academy, Russian Federation

109. Naphthalene preparation in the treatment of psoriasis and psoriatic arthritis.

Aida Pasic¹, Gordana Krnjevic Pezic², Goran Maricic², Aida Pasic¹, Kresimir Kostovic¹
¹University Hospital Center Zagreb, ²Naptalan Spec. Hospital for Med. Rehab., Croatia

110. Continuous antipsoriatic treatment with infliximab (IFX) throughout 8 years - a case report

Antje Viehweg¹, Gottfried Wozel¹
¹University Hospital Carl Gustav Carus, Germany

111. Childhood Generalized Pustular Psoriasis: A Report on Seven Cases

Ricardo Romiti¹, Sarah Oliveira¹, Luciana Maragno¹, Marcelo Arnone¹, Maria Denise Takahashi¹
¹HCFMUSP, Brazil

Health Economics and Health Policies

112. Methodological challenges in developing the first

European S3 guidelines on the systemic treatment of psoriasis

Delano Pathirana¹, Alexander Nast¹, Berthold Rzany¹
¹division of Evidence Based Medicine, Germany
²University of California-Davis, ³VA Medical Center Sacramento, United States

113. Employment is maintained and sick days decreased with etanercept in psoriasis/psoriatic arthritis patients

Robert Gnidecki¹, Tapani Tuomiranta², Sarolta Kárpáti³, Deborah Robertson⁴, Bruce Freundlich⁴, Charles Molta⁴, Robert Boggs⁴
¹Bispebjerg University Hospital, Denmark ²Hatanpää City Hospital, Finland ³Semmelweis University, Hungary ⁴Wyeth Research, United States

114. Statins in the treatment of psoriasis - friend or foe?

Andreas Colsman¹, Michael Sticherling²
¹University Hospitals of Erlangen, Germany ²Department of Dermatology Erlangen, Gibraltar

115. Quality of care and research profiles: Results of an International Psoriasis Council (IPC) exercise

Elizabeth Horn¹, Jonathan Barker², Richard Langley³, Alan Menter⁴, Alexa Kimball⁵
¹International Psoriasis Council, United States ²St. John's Institute of Dermatology, United Kingdom ³Dalhousie University, Canada ⁴Baylor University Medical Center, ⁵Harvard Medical School, United States

Late Breaking Abstracts

116. Adalimumab efficacy for psoriatic nail disease in BELIEVE.

D Thaci¹, J-P Ortonne², K Kragballe³, J-H Saurat⁴, P Spriegel⁵, K Unnebrink⁶, H Kupper⁶, EH Sasso⁶
¹Frankfurt, Germany; ²University of Nice, Nice, France; ³Århus Sygehus, Århus, Denmark; ⁴Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland; ⁵LEO Pharmaceutical Products Ltd. A/S, Ballerup, Denmark; ⁶Abbott GmbH & Co. KG, Ludwigshafen, Germany; ⁷Abbott Laboratories, Abbott Park, IL, USA.


Dear Participant,
SAS, the Official Airline of 2nd World Psoriasis & Psoriatic Arthritis Conference welcomes you to Stockholm, and hope that you will have a most successful and enjoyable conference!

We look forward to welcoming you on board again.

www.flysas.com



Scandinavian Airlines



**FOR 125 MILLION PEOPLE WITH A
HIDDEN DISEASE, HERE'S HOPE.**

worldpsoriasisday.com

World Psoriasis Day is presented by  International Federation of Psoriasis Associations, and supported by **Wyeth**



- A** Conference Venue; Folkets Hus & Norra Latin
- B** City Terminal, arrival for Arlanda Express and buses from Arlanda Airport
- C** Stockholm City Hall
- D** Opera Terrace

The Official Hotels booked

- | | |
|--------------------------------------|-----------------------------------|
| 1 Best Western Hotel Terminus | 7 Freys Hotel |
| 2 Comfort Hotel Stockholm | 8 Sheraton Stockholm |
| 3 Hotell Lilla Rådmannen | 9 Hotel Tegnérunden |
| 4 Clarion Hotel Sign | 10 Bentley Hotel |
| 5 Rica Hotel Kungsgatan | 11 Scandic Norra Bantorget |
| 6 Rica Hotel Stockholm | 12 Nordic Sea Hotel |

Welcome to IFPA



WORLDWIDE UNITY FOR PEOPLE LIVING WITH PSORIASIS



INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS

IFPA Main Sponsor



Corporate Supporters



Official Airline



Scandinavian Airlines